Related content

The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer

By Neal Joel W  

Future Oncology, Vol. 6, Iss. 12, 2010-12 ,pp. : 1827-1832

Future Medicine

Access to resources Recommend Favorite

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite

Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer

By Lam Elaine   Au Jessie   Otterson Gregory   Guillaume Wientjes M.   Chen Ling   Shen Tong   Wei Yong   Li Xiaobai   Bekaii-Saab Tanios   Murgo Anthony   Jensen Rhonda   Grever Michael   Villalona-Calero Miguel  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1019-1029

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

By Koizumi Tomonobu   Yoshiike Fumiaki   Inou Hitoshi   Hatayama Orie   Sasabayashi Mari   Tsushima Kenji   Yamamoto Hiroshi   Hayasaka Muneharu   Kubo Keishi  

Medical Oncology, Vol. 21, Iss. 2, 2004-06 ,pp. : 133-138

Humana Press, Inc

Access to resources Recommend Favorite

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

By            

Oncology Reports, Vol. 28, Iss. 3, 2012-01 ,pp. : 763-767

Spandidos Publications

Access to resources Recommend Favorite